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Abstract
Fepylated interferons have .reoent/v beer? cop-roved for treatment I
of .non-oegrafe•o Vvfo prorer ‘rr tam metier rts rot
experre.nced exacerbations of the Ir tver disease foi!owrng 8dm/n/er
— e
—r
t.rererd with these reoomrne rosa.
Introduction
Hepatitis C virus infhcts almost 200 million people worldwide. In
the L’S. chrome hepatitis C is estimated to affect nearly t’our million
people Recently. ilie 1—HA has ppruved Iwo formulations of
peevlated interferon. pegylated interferon alfa—2h (PEG—Intron®.
Scherine and pe® fated interferon al fa-2a PEGASt Sf2. Roche
for therapy of hepatitis C, increasing the therapeutic options avail
able to neat this disease Studies have shown the safet profiles of
both pee vl ated and nt n—pevm hoed interferon s to be si m i hir.
Although adverse effects are common with interf ron therapy. no
ervere adverse effects tin ique to the pegs med loon of thi dine has e
been described, We report two cases of adverse effects seen with the
use th pegy lated interferon alfa -2h.
Case I
A 7S- ear-rId .-\sian male was relb-rred Itt our deparuiient for
es aluation ot’chronie hepatitis C. eenot\pe I a. Prior to initiation of
treatment, his laboratory tests showed the folh iwing: alani ne a mi
notr,tnslerase AI F 241 CI. normal ranee \Ri ((--4(0. rm’pariate
uminotrrtnsf erase (ASTj 117 U/L (N 14 th 37). total hiliruhin iTB 1,0
nig/JL \R <150. hepatitis C viral lend b\ RN A PCR testilf2 I ICV
107 ni)0 copicsfmnL. hepatitis 13 surt,tce rtntihod\ tanti-Hhs
and total hepatitis A antibody (anti-HA\h positive.. \ biopsy of his
hr er showed chronic hcpatmtis itO mild steattths, erade 5 intl,tm
nratrrry chan es and stage. i: fibrosis, 1.-Ic was started s/i.? comhi:.n.ation
Ccrrresoondcnce o:
Kaunaka)cai, Hi 92748
F-mat: wthomam h5- rem
therrip of inierf’eron alfa—2b. 5 niillion units h subcutaneous
injection three times weekly, and oral ribasirin 1000 mg daih
I Rehetron®. Schering, Kenilworth. NJ.
The patient did not tolerate the combination treatment secondar\
to ribavirin—induced hemolstie anemia despite trials of dose adjust—
me ills and civ th ropomef in. Thus, the ii bay i ‘in w as ‘topped and he
\\ as continued on monotherap with tmerferon alfa—2b, Twenty
four weeks into his therapy, the patient was noted to have normal
Iransaminases and undetectable serum HCV R\A. Follow ing the
FDA approval of pegvlated interferon alfa—2h rPEG-1ntron®,
Schering. Kenilw tsrth. NJ 1. he was switched to this product at a dose
of 50 inn I .1> ne/kni w ceLL , The first dose was given two days
following his last dose of non—pegvlated interferon.
Lihorator evaluation alter two doses of this new therapr re—
sealed an AS”f of 25 Lf/L and an ALT of 20 C/L. After the sixth dose
ALT increased to 4(99 L’/L. Repeat testing after his ses enth dose
revealed an AST of 312 1-ilL, an ALT of 602 filL, and I-ICy RNA
was 551 .000eopies/niL. Given these results, treatment with pegvlated
umterferon was discontinued. During these seven weeks ofpegvlated
interferon therap patient reported only other medication to be a
single daily multivitamin. He denied used of other prescribed. Os er—
the—counter, herbal medicines or health supplements.
Thirteen days after his last pegvlated interferon dose, his AST had
decreased to 171 LUL and ALT it’ 576 C/I. B 21 da s. -\ST and
\IJ were 70 L/L and 204 I’lL, respecus eh - Alter one month AST
and ALT were 39 (ilL and 64 (ilL. respectively. The patient was
‘tarted hack on nion itherap\ with ut.in—pegy I ated interferon al fa— 2h
and his uransaminase levels have subsequently returned to normal
limitc, Repeat antinucleararmtmhodv AN.-\) and anti—smooth mnttscle
antuhod were negative. His albumin prothromhm time tPTj re—
niained normal throughout all treatments.
Case 2
A 49yearoll Caucasian male ss ith chr nie hepatitis C. v.enotvpe
lb. ‘.r ho had not responded to ri iou’. trial of combination
interferon alfru-2b and rihavirin, was referred tooureenterfor f’ttrther
sir aluation. Liver biopsy done twit ears pres ioti’.I\- res caled grade
5 inflamniatmoit and stageSfibrosis. [ reatmnent with I .0 ig/ks. body
a eight/day of suheutanes tus pev’r lated interferon alt’ar2h wac started
a ith time goal of Irrer cut m piogession of fihrosis and dccomnpen
sation of his liver disease. Medications prior to treatment initiation
included euialoprrsm and ratmmtidine. Patient denied ue of other
prescribed. or er-the--coumiter. hei’hal medici ties or health supple
in ntc urnnmdi Heir poorto ot follow inhiscmnvlr dos of peer I ttsd
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mierferon. 13e1/ire this treatment, his laborators s ames included
ALT56 U/L(NR fo4(h, AST63 U/L NR O-37t, TB 2.3 mg/dl (NR
<t.fo. alkahne phosphatase .-\iP (1$ Ufi. t\ R 3S 26. PT I 2.8
seconds NR I O.4 12.7). HCV RNA >1 ,000,000 copies/mi.. No
aseite or encep ilopaths \s as es idetmi.
After his first and only dose, his A Li and AST increased to 7 1 L/
Land 133 U/U. re pectis clv. and his TB doubled in value. Treatment
\Sas stopped aBer this first dose and repeat ietinc tss o weeks later
resealed ALT 84 U/U, AST 124 U/U. and TB 7.4 mg/dL. These
abnormal i ties peaked one n m th alter treatment at A [.T 2U U/i..
AST 156 U/U, TB 82) mg/dL, and PT 13.2 seconds. The patient’s
onl complaint 55 a severe prnritis throughout this tinte period. No
ascites orencepnalopath\ wases dent. Treatment ss dli LirsJdiol 60t)
me oralh twice dail was started ss ith subsequent rapid improve
ment in s mptoms and us er tem ahnormalttie. Thi’ee weeks after
initiation his laboratory resrilts revealed Al T l U/U. AST 162 U/
U. lB 2.8 mg/dL. and P1 12.4 seconds. Us aluamion for other eaLises
of acute hepatitis ss as tinrevealing: hepatitis B surface atitigen
HbsAu) nonreactive, anti- l-IAV 1gM necanve. hepatitis B coi’e
anti— H Be JoN! itegative ,ANA negatis e. nionospot necat i\:c. anti—
sniooth muscle atttihodv nonreactive, and anti—CMV 1gM negatis e.
No ahnormalitie of his serum albumin or All3 were noted during
the course of his disease and right upper qnadt’ant ultrasound done
dnrino bilirubin des ation ss as nitreinarkable.
Discussion
Two formulations of pegy lated i ntem’fer m are now available for the
therapy of chronic hepatitis C, PEG—Intron®, a covalent conjntate
olrecomhinant interteron alfa—2h with a 12 kilodalton kd polveth—
U tic is rol (PEG) moirts PEG N’, ‘t S ‘ t conlu,atL 01 mmci let on
alt’a-2a and a branched 1(t kd PEG chain. Interferon is believed to
work b hind mg to cell sLirt ace t’eceptors and Initiating a seqtence
of intracellular es cuts which result in suppression of cell prolifera
tion, inhibition of s mral replication in s mrus—intected cells, and
enhancemem of the phagoevtie activity ot macrophages and the
c totoxicity ofi ntphoc\tes tortaroeteells. Pegation ofinterfaron
results in decreased clearance and thus an increase in mean half—I fe
compared to non—peovlated drng. allowin once—vs eeklv dosing
without the prolonged sernmim trongh seen vs tIm non-peoslated drug.
The sustained les els obtained with pegs lated drug likely account for
the greater efficacy of these cotttpounds. \ds erse eft cets of once
weeklx dosed pegylated inmerterons have been similar to those of’
thrmee-sveeklvnon-peg\ lated drn. Comttton ads ere effects in
clude “flu-like symptoms - fatigue, headache, ins alias, rmgors,
ps rexma, amid nausea. I .ahoratot-v abnormalities occur less fm’equently,
tIme most conumon hcmnc neutropenm.u. llowed hs throntbocs tope
nia and aiteniia. Other umportatit adverse effects include anorexia,
nemiropschiatrie s mptoms including insomnia. irm’ttahilit\. and
depression. and alopecia. Adverse effects r lahotats us abnt umal i
tics severe enough to vsarraitt cessation of drug occurred in 0-I 1’4
of uhiect’. in two of the largest trials of pe’sleted versus non
peylated intet-feron The only ad.verse e ffee see.n more. fee
qtmentlv vs ith peevlated drug uppeam s to he injection stte muitlammua
tion. LIes anon of AIJ of2-5 times above baseline was seen in itmfe
of patients umeated vs ith PLG-lntm’on in re-nmrkcting trials. These
elesatious were transient and ssemeu ot aso1ateJ with detCuieratin
of other I mvem functions. Hvperhilim’uhinemia was reported mu ID-
14 of those patmemits reecivumg combined theraps with interferon
alfa—2b and rihavirin.
Case I inns be the first case in the literature of ses crc \vorsenino
of hepatitis t’ollowing the initiation of pegslated interterorm, His
Ai.T. vs hmle ouR 2.5 times mis pm’ett’eatmemtt les el. m’ose 30 times that
of the Ic s el seen on non-pegs kited interfe’m’on therapy. ‘I he mtiarkcd
elevation in All’ and loss of HCV RNA suppression after starting
PEG-lmitron/. indicates liver niur\ and rmmteommmrolled m’eplication of
the virus. The cause of this severe worseningomichange of interferon
therapy is umielear hut could possibli be dime to au aiutoittttnitiue
mechanism, or less likels to another infection or intoxicatmoil se iltO
not identi Iv.
Case 2 demonstrates acute cholest:isms tollowimme admimmnist ration
of PEG—lntron® as manifest by the increase in both ALT and serum
hilirubin. These indices treurted toward the normal range after the
prompt removal of’the drug and treatment ss ith itrsodiol. The nmarked
imupros emnemit with mirsodiol tm’eatment vs as surprisi ic amid encoui’ae
imig. Eurtherstudiesame miceded toes aluate the roleofthis medication
in patients with acute hepatic iniurs due to pegvlated interferon. No
othmereause forthe acute ahuoritmalities in Otis persomi vs as idemitilmed.
These eases represent the first report of severe adverse liver reac
tions to the pee hued tntert’eron. PEG—Inti-on® in its use mu the
treattument of hepatitis C. Other likely causes of exacerhatiomi were
rutled out in these cases leaving the only ohs ions variable in each
case the umtrodrtetmomi of this ness drug. These m’csimlts call br igilant
monitoring of patients treated with pegvlated interferons, especially
PEG—Introit® and prompt ss mthdrass at of these drug mu patmeruts vs ho
detrionstrate an acute
inemease iii ALT.
References
,1
164
Aloha Laboratories, Inc.
When results count
CAP accredited laboratory
specializing in Anatomic
Pathology
Qualit and Service
1)avid \i. Amberger. M.D.
Faboratory I)irectory
Phone: t808) 842—6600
Fax: t808 S48-0663
J/-N1iiI: resultsQvalohalahc.t’oni
http:/Is w w.alolialabs.coni
